Jascayd approval has been granted in Japan and recommended in the European Union for treating adults with two types of pulmonary fibrosis.

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Living with a chronic and progressive disease like pulmonary fibrosis (PF) can be challenging, and there are many issues a person with PF needs to consider, including lifestyle changes, coping with ...

Ofev (nintedanib), an oral medication by Boehringer Ingelheim, is now approved to treat people with progressive fibrosing interstitial lung diseases (ILDs) in the U.S. and Canada. Ofev is the first ...

Hyperbaric oxygen therapy can counteract some of the key features of pulmonary fibrosis (PF) in mice and human lung cells, a recent study reveals. The findings suggest this treatment, involving the ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring in people with idiopathic pulmonary fibrosis (IPF). The new generic nintedanib ...